TrialThe Lancet. Oncology2021

Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study.

Justin F Gainor et al.PubMed ↗Publisher ↗

No numbers read from the abstract.